CONTACT
+91 80 2808 2808
info@biocon.com

Biocon Receives EIR from US FDA for Visakhapatnam API Facility

  • Fri, 30-Aug-2024
  • Posted by: BIOCON
No Comments

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

 

Visakhapatnam, Andhra Pradesh, India, August 30, 2024

“This is to inform you that the Company has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (US FDA), for our greenfield API facility (Site 6), located at Visakhapatnam, Andhra Pradesh.

This is based on a pre-approval inspection conducted by the agency between the 10th and 14th of June, 2024, and now allows us to commence commercial supplies from this facility to the U.S. market.”


Download Company StatementDownload Company Statement
Author: BIOCON

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2024, Biocon. All Rights Reserved
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>